Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2014

View Archived Issues

Novel pan tyrosine kinase receptor inhibitor identified for the treatment of cancer

RXi Pharmaceuticals updates on phase II program of RXI-109 in scar recurrence prevention

Report of phase I evaluation of a STAT3 ASO for hepatocellular carcinoma

Takeda describes PDE10A inhibitor TAK-063

Phase I study initiated for ProMetic IV plasminogen

SOV Therapeutics' oral testosterone undecanoate meets phase IIb study endpoints

Pfizer starts phase II trial of anti-myostatin antibody in DMD

Further phase III data reveal efficacy of LCZ-696 in hypertension and heart failure

Bayer presents novel TTK inhibitors for cancer

NESP approved for anemia with myelodysplastic syndromes in Japan

Kyowa Hakko Kirin receives additional indication approval for Poteligeo in Japan

Prima BioMed completes acquisition of Immutep

Kadcyla fails to show superiority to Herceptin plus taxane therapy in untreated breast cancer

Polaris' ADI-PEG20 receives E.U. orphan drug status for MPM

Researchers report phase I results on taselisib in breast cancer

Medeia Therapeutics discloses new cytoprotectants

Johns Hopkins University patents novel aptamers for sickle cell anemia

HCV treatment designed by French and U.S. organizations

European orphan drug designation for Halozyme's PEGPH-20 in pancreatic cancer

FDA approves Lynparza, and companion diagnostic, for germline BRCA-mutated advanced ovarian cancer

EMA committee recommends approval of Xadago to treat mid- to late-stage Parkinson's disease

CHMP backs approval of Orexigen's naltrexone/bupropion for weight management

U.S. approval for Cubist's ceftolozane/tazobactam for cUTI and cIAI

FDA approves Rapivab for acute uncomplicated influenza

Intravenous administration of Erwinaze obtains U.S. approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...